Scholarlink

Aim <p>This study investigates the efficacy and safety of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) in treating hormone receptor-positive (HR +), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.</p> Methods <p>A systematic review of randomized clinical trials (RCTs) from 2015 to 2024 was conducted using databases such as PubMed, Google Scholar, Embase, and Cochrane. Data were collected on treatment outcomes, including complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), overall response rate (ORR), and treatment-related adverse events (TRAEs). Analysis was performed using Review Manager 5.4.1, following PRISMA guidelines, with registration in the PROSPERO database (ID: CRD42023471168).</p> Results <p>1223 studies screened, 13 met inclusion criteria. CDK4/6i + ET significantly reduced PD rates and increased SD compared to ET + chemotherapy. No significant differences were observed in CR, PR, or SD between the groups. CDK4/6i + ET demonstrated a favorable safety profile with fewer high-grade TRAEs but had a higher incidence of grade 3–4 adverse events than ET alone.</p> Conclusion <p>CDK4/6i combined with ET improves disease control by decreasing progression and increasing stability, though it shows a lower PR rate than ET + chemotherapy in HR + /HER2&#xa0;− advanced breast cancer. These findings underscore the need to balance efficacy with tolerability when selecting treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of cyclin-dependent kinases 4 and 6 inhibitors in the treatment of HR +/HER2 − advanced breast cancer: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月24日

查看全文
  • Isah Adamu Danbala,
  • Xu Wang,
  • Yuting Su,
  • Haowen Tang,
  • Wanying Sheng,
  • Zakari Shaibu,
  • Iliyasu Isah,
  • Xiao Yuan

摘要

Aim

This study investigates the efficacy and safety of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) in treating hormone receptor-positive (HR +), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.

Methods

A systematic review of randomized clinical trials (RCTs) from 2015 to 2024 was conducted using databases such as PubMed, Google Scholar, Embase, and Cochrane. Data were collected on treatment outcomes, including complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), overall response rate (ORR), and treatment-related adverse events (TRAEs). Analysis was performed using Review Manager 5.4.1, following PRISMA guidelines, with registration in the PROSPERO database (ID: CRD42023471168).

Results

1223 studies screened, 13 met inclusion criteria. CDK4/6i + ET significantly reduced PD rates and increased SD compared to ET + chemotherapy. No significant differences were observed in CR, PR, or SD between the groups. CDK4/6i + ET demonstrated a favorable safety profile with fewer high-grade TRAEs but had a higher incidence of grade 3–4 adverse events than ET alone.

Conclusion

CDK4/6i combined with ET improves disease control by decreasing progression and increasing stability, though it shows a lower PR rate than ET + chemotherapy in HR + /HER2 − advanced breast cancer. These findings underscore the need to balance efficacy with tolerability when selecting treatment strategies.